Published in Can J Gastroenterol on November 01, 2013
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
FibroScan® access in Canada: Time for reform, a call for universal access. Can J Gastroenterol Hepatol (2015) 0.98
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
Out with the old and in with the new: hepatic fibrosis assessment in Canada. Can J Gastroenterol Hepatol (2014) 0.80
Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis. Ont Health Technol Assess Ser (2015) 0.76
Why most hepatologists do not perform percutaneous liver biopsy. Re: Aljawad M, Yoshida EM, Uhanova J, Marotta P, Chandok N. Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol 2013;27:e31-34. Can J Gastroenterol Hepatol (2014) 0.75
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Liver biopsy. Hepatology (2009) 7.61
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology (2008) 3.67
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut (1999) 3.10
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol (2010) 2.57
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol (2007) 2.34
Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int (2008) 2.09
Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol (1996) 2.01
Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology (2012) 1.93
Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology (2013) 1.64
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology (1996) 1.48
Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. Dig Dis Sci (1998) 1.41
Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol (1995) 1.36
Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists. Am J Gastroenterol (2002) 1.33
Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology (2010) 1.26
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol (2010) 1.19
A survey of current liver biopsy practice patterns. J Clin Gastroenterol (2002) 1.03
A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. Clin Gastroenterol Hepatol (2008) 1.02
Ultrasound-guided liver biopsy in real life: comparison of same-day prebiopsy versus real-time ultrasound approach. J Gastroenterol Hepatol (2007) 0.89
Liver biopsy in the mid-1990s: questions and answers. Semin Liver Dis (1995) 0.87
Percutaneous liver biopsy: what is the current approach? Results of a questionnaire survey. Dig Dis Sci (2001) 0.85
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Adverse events among medical patients after discharge from hospital. CMAJ (2004) 7.89
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Physician visits, hospitalizations, and socioeconomic status: ambulatory care sensitive conditions in a canadian setting. Health Serv Res (2005) 2.67
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol (2002) 2.10
Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl (2013) 2.03
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02
Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Occult hepatitis B virus infection in a North American community-based population. J Hepatol (2005) 1.64
Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Granulomatous hepatitis associated with etanercept therapy. J Rheumatol (2008) 1.56
Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth (2005) 1.55
Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation (2004) 1.51
Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49
Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol (2005) 1.47
Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl (2013) 1.46
Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl (2004) 1.42
Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Clin Transplant (2007) 1.39
Representing complexity well: a story about teamwork, with implications for how we teach collaboration. Med Educ (2012) 1.38
Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology (2004) 1.30
Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl (2007) 1.27
Clozapine-induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol (2009) 1.22
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma (2005) 1.21
Choledochal cysts. Part 3 of 3: management. Can J Surg (2010) 1.21
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
Gastric polyps in patients with portal hypertension. Eur J Gastroenterol Hepatol (2011) 1.16
Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol (2010) 1.14
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10
Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol (2011) 1.09
Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci (2005) 1.08
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol (2012) 1.05
Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg (2009) 1.03
Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation (2011) 1.03
Acute fatty liver of pregnancy. Can J Gastroenterol (2006) 1.03
Effect of a nurse team coordinator on outcomes for hospitalized medicine patients. Am J Med (2005) 1.02
Defining readmission risk factors for liver transplantation recipients. Gastroenterol Hepatol (N Y) (2011) 1.01
Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl (2002) 1.01
Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology (2011) 1.00
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00
Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review. Ann Hepatol (2012) 0.99
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Perioperative neurological complications after liver transplantation are best predicted by pre-transplant hepatic encephalopathy. Neurocrit Care (2008) 0.98
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol (2010) 0.94
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol (2005) 0.93
Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci (2002) 0.93
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
Long-term outcomes of emergency liver transplantation for acute liver failure. Liver Transpl (2009) 0.91
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91
Late acute celiac and hepatic artery thrombosis with portal vein thrombosis resulting in hepatic infarction 12 years post orthotopic liver transplantation. Ann Hepatol (2009) 0.91
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol (2005) 0.89
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy (2008) 0.89
Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl (2009) 0.89
Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol (2009) 0.88
Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after transplantation. Am J Cardiol (2004) 0.87
Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci (2006) 0.86
Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol (2007) 0.86
Prospective evaluation of the role of quantitative Doppler ultrasound surveillance in liver transplantation. Liver Transpl (2004) 0.86
Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Ann Hepatol (2010) 0.86
Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl (2003) 0.85
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
Transient improvement of acquired hepatocerebral degeneration with parkinsonian symptoms after failed liver transplant: case report and literature review. Exp Clin Transplant (2011) 0.85
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol (2006) 0.85
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int (2009) 0.84
GABA-B receptor activation inhibits the in vitro migration of malignant hepatocytes. Can J Physiol Pharmacol (2011) 0.84
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol (2013) 0.83
Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia. Can J Gastroenterol (2011) 0.83
First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol (2013) 0.83
Response to endoscopic therapy for biliary anastomotic strictures in deceased versus living donor liver transplantation. Hepatobiliary Pancreat Dis Int (2013) 0.83
Recurrent ectopic pancreatitis of the jejunum and mesentery over a 30-year period. Hepatobiliary Pancreat Dis Int (2011) 0.82
Utility of hepatic phosphorus-31 magnetic resonance spectroscopy in a rat model of acute liver failure. J Investig Med (2003) 0.82
Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. Transplantation (2006) 0.82
Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol (2006) 0.82
Effects of daily, light and moderate-heavy ethanol exposure on extent of hepatic injury and recovery following toxin-induced acute hepatitis in rats. Dig Dis Sci (2003) 0.82
Hepatic metastasis from adrenocortical carcinoma fifteen years after primary resection. Saudi J Gastroenterol (2012) 0.81
Abdominal pain as the initial and sole clinical presenting feature of systemic lupus erythematosus. Can J Gastroenterol (2003) 0.81